Forum Topic News
  • Conversation: AZ buys Ionis’ NASH candidate

    • April 10, 2018 12:11 PM BST
      • Post(s)

      AZ buys Ionis’ NASH candidate

      AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million.
      The move, which builds on an existing strategic partnership between the firms, was triggered by the drug’s advance into development, Ionis said.
      IONIS-AZ6-2.5-LRx/AZD2693 is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease.
      AZ will pay a $30 million license fee to Ionis, and takes over responsibility for further development and commercialization of the drug.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel